WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally

PR Newswire10:30

MIIT: By 2030, a preliminary collaborative development system for the entire industrial chain of traditional Chinese medicine will be established.

The Ministry of Industry and Information Technology and seven other departments released the 'Implementation Plan for High-Quality Development of the Traditional Chinese Medicine (TCM) Industry (2026-2030)', proposing that by 2030, a preliminary collaborative development system for the entire TCM industrial chain will be formed. The continuous and stable supply capacity of key TCM raw materials will be further enhanced, and the levels of digital intelligence and green practices will significantly improve. Breakthroughs will be achieved in a number of key technologies, and the level of industrial collaborative innovation will notably increase. Development quality will markedly improve, with steady growth in the scale and benefits of the TCM industry, and a clear rise in the degree of industrial intensification. Quality management standards will significantly improve, fostering a group of leading TCM industrial enterprises with outstanding leadership capabilities, as well as cultivating 60 high-quality products

AASTOCKSFeb 5 17:06

Wuxi Biologics (Cayman) Stock Advances 2.6% in Hong Kong

Dow JonesFeb 5 16:31

The Cyberspace Administration of China is intensifying its efforts to address false and misleading online information related to the centralized procurement of pharmaceuticals and medical consumables.

The Cyberspace Administration of China (CAC), in collaboration with the National Healthcare Security Administration (NHSA), has recently intensified efforts to address online false and misleading information related to bulk procurement of pharmaceuticals. A number of accounts that have tarnished the reputation of centralized procurement, incited public anxiety, or misled the public have been dealt with according to relevant laws and regulations. Examples of typical cases include: fabricating false information to defame centralized procurement policies for the purpose of gaining traffic;煽动社会情绪，制造公众焦虑；and deliberately associating non-procurement products with centralized procurement to mislead the public. The relevant accounts have already been subjected to appropriate measures as per legal and regulatory frameworks. The CAC emphasized that policies on the bulk procurement of medicines and medical consumables are closely tied to the vital interests of the public, and the fabrication and dissemination of false o

AASTOCKSFeb 5 11:39

The National Medical Products Administration (NMPA) announced that it will provide substantial support for the innovation and development of the bio-manufacturing industry during the 15th Five-Year Plan period.

The National Medical Products Administration (NMPA) stated that during the 15th Five-Year Plan period, it will strongly support innovation and development in the biomanufacturing industry, promoting the transformation of the pharmaceuticals industry from 'follow-up innovation' to 'systematic innovation,' from 'scale-and-speed-driven growth' to 'quality-and-efficiency-driven growth,' and from 'traditional business models' to 'digitalized supply chains.' The authority noted that this year, the country will closely monitor frontier technology areas such as new target and mechanism-based drugs, AI-driven drug discovery, as well as cell and gene therapies. Through four expedited approval pathways, the NMPA aims to accelerate drug market entry. Additionally, efforts will be made to effectively implement a data protection system for clinical trial data and establish policies specifically targeting pediatric medicines and treatments for rare diseases.

AASTOCKSFeb 4 17:42

UOB Kay Hian: Maintains a constructive view on the mid-term market outlook. Alibaba (09988.HK), Ganfeng Lithium (01772.HK), and Minth Group (00425.HK) added to the buy list; recommends selling Meituan (03690.HK).

UOB Kay Hian stated that China's stock market rebounded in January, with the Hang Seng Index and MSCI China Index rising 6.9% and 5% month-on-month, respectively. However, the overall increase was limited by the "national team," led by Central Huijin, selling $68 billion worth of shares. Among the bank’s top picks for January, Wuxi Bio (02269.HK) and Smart Connections Technology (01523.HK), both rated as buys, delivered returns of 17.7% and 16.6%, respectively. UOB Kay Hian noted that market conditions in February may remain volatile, but it maintains a constructive view in the medium term. The exponential rise in gold and silver prices over the past two months saw a sharp correction in early February.

AASTOCKSFeb 4 11:46